Cavernous hemangioma of retina

Summary

Cavernous hemangioma of retina (MONDO:0021281) is a disease. A subtype of cavernous hemangioma of face — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cavernous hemangioma of retina
Mondo ID	MONDO:0021281
NCIT	C4921
SNOMED CT	312937006
UMLS	C0730304
MedGen	152678
GARD	0025304
Anatomy (UBERON)	UBERON:0000966
Is cancer (heuristic)	no

Also known as: cavernous angioma of retina · cavernous angioma of the retina · cavernous hemangioma of the retina · retina cavernous angioma · retina cavernous hemangioma · retinal cavernous angioma · retinal cavernous hemangioma

Disease family

This is a subtype of cavernous hemangioma of face. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › cavernous hemangioma › cavernous hemangioma of face › cavernous hemangioma of retina

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.